NCT00507858View on ClinicalTrials.gov

Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Head and Neck Cancer
Interventions
DRUG

Pemetrexed

Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks

DRUG

Dexamethasone

Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00507858 - Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer | Biotech Hunter | Biotech Hunter